Kirilys Therapeutics

Kirilys Therapeutics, Inc. is a preclinical-stage biopharmaceutical company dedicated to developing a variety of precision oncology assets. Kirilys' initial asset is KRLS-017, a novel CDK7 inhibitor with the potential to improve the treatment of multiple cancers.